STOCK TITAN
  1. Home
  2. Sec-filings
  3. TLX
  4. [Form 3] Telix Pharmaceuticals Ltd Initial Statement of Beneficial Ownership

Telix (TLX) CMO discloses 373,133 shares plus PSAR and share rights

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Telix Pharmaceuticals’ Group Chief Medical Officer, Cade David Norman, has reported his existing equity interests in the company. He holds 373,133 Ordinary Shares directly, along with several derivative awards tied to Telix ordinary shares.

These include Performance Share Appreciation Rights over 78,189 underlying Ordinary Shares at A$4.9500 per share expiring on April 4, 2027, and 84,293 underlying Ordinary Shares at A$6.9000 per share expiring on December 21, 2027. He also holds Share Rights over 1,080 underlying Ordinary Shares expiring on March 31, 2028 and 11,486 underlying Ordinary Shares expiring on March 31, 2029. Footnotes state these awards were granted between April 2022 and March 2026, with vesting dates in 2025–2027 and that each Share Right represents the contingent right to receive one ordinary share, subject to continued employment and forfeiture if employment is terminated for cause.

Positive

  • None.

Negative

  • None.
Insider Cade David Norman
Role Group Chief Medical Officer
Type Security Shares Price Value
holding Performance Share Appreciation Rights (right to buy) -- -- --
holding Performance Share Appreciation Rights (right to buy) -- -- --
holding Share Rights -- -- --
holding Share Rights -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Performance Share Appreciation Rights (right to buy) — 78,189 shares (Direct); Share Rights — 1,080 shares (Direct); Ordinary Shares — 373,133 shares (Direct)
Footnotes (1)
  1. he performance share appreciation rights (PSARs) were granted on April 5, 2022, and became vested and exercisable on March 6, 2025 Conversion price is reported in Australian Dollars. The PSARs were granted on April 25, 2023, and became vested and exercisable on March 12, 2026. The share rights (SRs) were granted on January 1, 2025, and became vested and exercisable on March 5, 2026. The SRs were granted on March 18, 2026 and will become vested and exercisable in approximately February or March 2027. The SRs are subject to forfeiture where employment is terminated for cause only, subject to continued service with the issuer. The vesting date will be communicated to the reporting person following testing that will occur after the audited calendar year 2026 financial results announcement. Each SR represents the contingent right to receive one ordinary share.
Direct Ordinary Shares 373,133 shares Direct holdings reported by Group Chief Medical Officer
PSAR underlying shares at A$4.9500 78,189 underlying shares Exercise price A$4.9500, expiration April 4, 2027
PSAR underlying shares at A$6.9000 84,293 underlying shares Exercise price A$6.9000, expiration December 21, 2027
Share Rights 2028 1,080 underlying shares Share Rights expiring March 31, 2028
Share Rights 2029 11,486 underlying shares Share Rights expiring March 31, 2029
PSAR 2022 grant vesting Vested March 6, 2025 PSARs granted April 5, 2022 became vested and exercisable
PSAR 2023 grant vesting Vested March 12, 2026 PSARs granted April 25, 2023 became vested and exercisable
Performance Share Appreciation Rights financial
"Performance Share Appreciation Rights (right to buy)"
Share Rights financial
"The share rights (SRs) were granted on January 1, 2025"
vested and exercisable financial
"became vested and exercisable on March 6, 2025"
contingent right to receive one ordinary share financial
"Each SR represents the contingent right to receive one ordinary share."
subject to forfeiture financial
"The SRs are subject to forfeiture where employment is terminated for cause only"
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Cade David Norman
(Last)(First)(Middle)
C/O TELIX PHARMACEUTICALS LTD
55 FLEMINGTON RD
(Street)
NORTH MELBOURNE3051
(City)(State)(Zip)
AUSTRALIA
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
Telix Pharmaceuticals Ltd [ TLX ]
3a. Foreign Trading Symbol
[TLX] 		5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Group Chief Medical Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares373,133D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance Share Appreciation Rights (right to buy) (1)04/04/2027Ordinary Shares78,189$4.95(2)D
Performance Share Appreciation Rights (right to buy) (3)12/21/2027Ordinary Shares84,293$6.9(2)D
Share Rights (4)03/31/2028Ordinary Shares1,080$0D
Share Rights (5)03/31/2029Ordinary Shares11,486$0D
Explanation of Responses:
1. he performance share appreciation rights (PSARs) were granted on April 5, 2022, and became vested and exercisable on March 6, 2025
2. Conversion price is reported in Australian Dollars.
3. The PSARs were granted on April 25, 2023, and became vested and exercisable on March 12, 2026.
4. The share rights (SRs) were granted on January 1, 2025, and became vested and exercisable on March 5, 2026.
5. The SRs were granted on March 18, 2026 and will become vested and exercisable in approximately February or March 2027. The SRs are subject to forfeiture where employment is terminated for cause only, subject to continued service with the issuer. The vesting date will be communicated to the reporting person following testing that will occur after the audited calendar year 2026 financial results announcement. Each SR represents the contingent right to receive one ordinary share.
Remarks:
Ex. 24 - Power of Attorney
/s/ Oliver Newman, on behalf of Dr. David Cade, Group CMO04/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Telix Pharmaceuticals (TLX) Group Chief Medical Officer hold according to this Form 3?

The Group Chief Medical Officer, Cade David Norman, directly holds 373,133 Ordinary Shares of Telix Pharmaceuticals. He also reports multiple derivative awards, including Performance Share Appreciation Rights and Share Rights over additional underlying ordinary shares that may be acquired if vested and exercised.

What Performance Share Appreciation Rights does Cade David Norman report in Telix (TLX) Form 3?

He reports Performance Share Appreciation Rights over 78,189 underlying Ordinary Shares at A$4.9500 expiring April 4, 2027, and 84,293 underlying Ordinary Shares at A$6.9000 expiring December 21, 2027. Footnotes state these PSARs were granted in 2022 and 2023 and later became vested and exercisable.

What Share Rights are disclosed for Telix (TLX) CMO in this filing?

He reports Share Rights over 1,080 underlying Ordinary Shares expiring March 31, 2028 and 11,486 underlying Ordinary Shares expiring March 31, 2029. Each Share Right represents a contingent right to receive one ordinary share, subject to vesting conditions and potential forfeiture if employment is terminated for cause.

How are the Telix (TLX) Share Rights for the CMO structured and when do they vest?

Footnotes state Share Rights granted January 1, 2025 became vested and exercisable on March 5, 2026. Additional Share Rights granted March 18, 2026 will vest in approximately February or March 2027, after testing that follows the audited calendar year 2026 financial results announcement.

Are the Telix (TLX) Share Rights subject to forfeiture for the Group Chief Medical Officer?

Yes. Footnotes explain that certain Share Rights granted on March 18, 2026 are subject to forfeiture if employment is terminated for cause. These awards also require continued service, and the final vesting date will be communicated after testing linked to 2026 audited financial results.

In what currency are Telix (TLX) CMO’s Performance Share Appreciation Rights exercise prices reported?

A footnote clarifies that the conversion price for the Performance Share Appreciation Rights is reported in Australian Dollars. This applies to the exercise prices of A$4.9500 and A$6.9000 associated with the underlying Telix ordinary shares disclosed in the Form 3.